Matritech submits 510(k) clearance for NuMa test:
This article was originally published in Clinica
Matritech has submitted a 510(k) premarket notification to the FDA for its blood-based NuMa test kit. The test is used in the management of colon cancer and is based on the US company's Nuclear Matrix Protein (NMP) technology which correlates levels of NMPs in body fluids to the presence of cancer.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.